Alexandra E Kovach, Daria Komova, Albert Itov, Maria Gaskova, Irina Kalinina, Kirill Voronin, Yulia Rumiantseva, Alexander Karachunskii, Michael Maschan, Alexey Maschan, Galina Novichkova, Yulia Olshanskaya, Deepa Bhojwani, Gordana Raca, Elena Zerkalenkova
{"title":"小儿治疗相关血液肿瘤显示出 KMT2A 重排和淋巴细胞表型的富集。","authors":"Alexandra E Kovach, Daria Komova, Albert Itov, Maria Gaskova, Irina Kalinina, Kirill Voronin, Yulia Rumiantseva, Alexander Karachunskii, Michael Maschan, Alexey Maschan, Galina Novichkova, Yulia Olshanskaya, Deepa Bhojwani, Gordana Raca, Elena Zerkalenkova","doi":"10.1080/10428194.2024.2376166","DOIUrl":null,"url":null,"abstract":"<p><p>In children, therapy-related hematologic neoplasms (t-HN) are uncommon. Many are driven by genetic events independent of clonal hematopoiesis. We sought to understand the clinical and genetic factors of pediatric t-HN in a large independent cohort. Fifty-six t-HN were retrospectively identified. Chromosome microarray, next-generation and/or RNA sequencing were performed. Patients had primary hematologic, solid, or central nervous system tumors. t-HN included myeloid (t-MN) and lymphoblastic (t-ALL) phenotypes. Approximately half of the cases harbored <i>KMTA2A</i> rearrangement (<i>KMT2A</i>r). Among t-HN without <i>KMT2A</i>r, genetic drivers were heterogeneous, including diverse fusions or aneuploidy. Approximately 18% harbored 17p deletions and/or <i>TP53</i> mutations. EFS/OS was not associated with t-HN lineage or <i>KMT2A</i>r, but HSCT was associated with improved EFS and OS. We detail one of the largest cohorts to date of pediatric t-HN, confirming frequent <i>KMT2A</i>r and t-ALL.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pediatric therapy-related hematologic neoplasms show enrichment for <i>KMT2A</i> rearrangement and lymphoblastic phenotype.\",\"authors\":\"Alexandra E Kovach, Daria Komova, Albert Itov, Maria Gaskova, Irina Kalinina, Kirill Voronin, Yulia Rumiantseva, Alexander Karachunskii, Michael Maschan, Alexey Maschan, Galina Novichkova, Yulia Olshanskaya, Deepa Bhojwani, Gordana Raca, Elena Zerkalenkova\",\"doi\":\"10.1080/10428194.2024.2376166\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In children, therapy-related hematologic neoplasms (t-HN) are uncommon. Many are driven by genetic events independent of clonal hematopoiesis. We sought to understand the clinical and genetic factors of pediatric t-HN in a large independent cohort. Fifty-six t-HN were retrospectively identified. Chromosome microarray, next-generation and/or RNA sequencing were performed. Patients had primary hematologic, solid, or central nervous system tumors. t-HN included myeloid (t-MN) and lymphoblastic (t-ALL) phenotypes. Approximately half of the cases harbored <i>KMTA2A</i> rearrangement (<i>KMT2A</i>r). Among t-HN without <i>KMT2A</i>r, genetic drivers were heterogeneous, including diverse fusions or aneuploidy. Approximately 18% harbored 17p deletions and/or <i>TP53</i> mutations. EFS/OS was not associated with t-HN lineage or <i>KMT2A</i>r, but HSCT was associated with improved EFS and OS. We detail one of the largest cohorts to date of pediatric t-HN, confirming frequent <i>KMT2A</i>r and t-ALL.</p>\",\"PeriodicalId\":18047,\"journal\":{\"name\":\"Leukemia & Lymphoma\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia & Lymphoma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10428194.2024.2376166\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2024.2376166","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Pediatric therapy-related hematologic neoplasms show enrichment for KMT2A rearrangement and lymphoblastic phenotype.
In children, therapy-related hematologic neoplasms (t-HN) are uncommon. Many are driven by genetic events independent of clonal hematopoiesis. We sought to understand the clinical and genetic factors of pediatric t-HN in a large independent cohort. Fifty-six t-HN were retrospectively identified. Chromosome microarray, next-generation and/or RNA sequencing were performed. Patients had primary hematologic, solid, or central nervous system tumors. t-HN included myeloid (t-MN) and lymphoblastic (t-ALL) phenotypes. Approximately half of the cases harbored KMTA2A rearrangement (KMT2Ar). Among t-HN without KMT2Ar, genetic drivers were heterogeneous, including diverse fusions or aneuploidy. Approximately 18% harbored 17p deletions and/or TP53 mutations. EFS/OS was not associated with t-HN lineage or KMT2Ar, but HSCT was associated with improved EFS and OS. We detail one of the largest cohorts to date of pediatric t-HN, confirming frequent KMT2Ar and t-ALL.
期刊介绍:
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor